Abstract:Introduction: Relapsed or refractory (r/r) peripheral T cell lymphoma (PTCL) is an aggressive lymphoma with poor prognosis. Most approved therapies demonstrated overall response rates (ORR) < 30% and short progression free survival. DZD4205 (AZD4205), a potent and highly selective JAK1 inhibitor, demonstrated profound anti-tumor activity in T lymphoma cells in vitro and tumor xenograft in vivo, suggesting its potential as a therapeutic option for this unmet medical need. In this abstract, we reported the preliminary data from the ongoing phase I/II study of DZD4205 treating patients with r/r PTCL (NCT04105010, JACKPOT8). Methods: The JACKPOT8 study is an open label single arm study, which aims to assess the safety, tolerability and anti-tumor efficacy of DZD4205 in r/r PTCL. This study includes two parts. In Part A, subjects with r/r PTCL who relapsed from or were refractory/intolerant to systemic therapy were enrolled and dosed with DZD4205 at 150 mg or 250 mg once daily. In Part B, subjects received DZD4205 at a defined dose. Safety and efficacy were assessed according to CTCAE version 5.0 and 2014 Lugano classification, respectively. Results: As of December 7, 2020, a total of 47 subjects with r/r PTCL were dosed with DZD4205 (150 mg, n = 31; 250 mg, n = 16). Median age was 62.0 years (range: 29 - 79), and median prior systemic therapies were 2 lines (range: 1 - 8). Six subjects had undergone prior hematopoietic stem cell transplantation. Sixteen subjects had bone marrow involvement at the baseline. Histological subtypes included PTCL not otherwise specified (42.6%), angioimmunoblastic T cell lymphoma (42.6%), ALK negative anaplastic large cell lymphoma (6.4%), extra-nodal nasal NK/T cell lymphoma (6.4%) and monomorphic epitheliotropic intestinal T cell lymphoma (2.1%). Preliminary data showed that 41 subjects (87.2%) experienced treatment emergent adverse events (TEAEs), among whom 24 (51.1%) had ≥ grade 3 TEAEs. According to investigators, 16 subjects (34.0%) had ≥ grade 3 TEAEs possibly related to DZD4205. The most common (> 10%) ≥ grade 3 TEAEs included thrombocytopenia (23.4%), neutropenia (17.0%), and pneumonia (12.8%). Most TEAEs were manageable and reversible with or without dose modifications. As of December 7, 2020, 42 subjects (150 mg, n = 27; 250 mg, n = 15) completed at least one post-treatment tumor assessment. At 150 mg, 14 subjects showed tumor response, with ORR of 51.9%, among whom 6 (22.2%) had complete response. At 250 mg, 6 subjects showed tumor response, with ORR of 40.0%. Tumor response was observed in various subtypes. The median duration of response (DoR) was not reached, and the longest DoR was > 12 months. Patient enrolment is ongoing. The research was funded by: The research was funded by Dizal (Jiangsu) Pharmaceutical Co., Ltd. Ongoing Trial Keywords: Molecular Targeted Therapies, Aggressive T-cell non-Hodgkin lymphoma, Molecular Targeted Therapies No conflicts of interests pertinent to the abstract. SESSION 9: MANTLE CELL LYMPHOMA

Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway.

Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors.

N -(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms

Discovery of N-((3r,4r)-4-Fluoro-1-(6-((3-Methoxy-1-Methyl-1h-Pyrazol-4-Yl)Amino)-9-M Ethyl-9h-Purin-2-Yl)Pyrrolidine-3-Yl)Acrylamide (Pf-06747775) Through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic Egfr Mutants with Selectivity over Wild-Type Egfr

Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors.

Combination of ligand‐based and structure‐based virtual screening for the discovery of novel Janus kinase 2 inhibitors against philadelphia-negative myeloproliferative neoplasms

Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2/BRD4(BD2) dual target inhibitors

Design, synthesis and SAR study of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms

Dual CK1/PI3K Inhibitor HZ-H08905, Exhibits As a Potential Therapeutic Strategy for Hematologic Malignancies

New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms

Early safety and efficacy data from a phase i/ii trial of dzd4205, a selective jak1 inhibitor, in relapsed/refractory peripheral t‐cell lymphoma

Preclinical Evaluation Of Hm-018, A Potent And Selective Jak Inhibitor In The Treatment Of Myloproliferative Disorders

Discovery of 6-[(3 S,4 S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera

Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2

Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms

Molecular modeling of novel 2-aminopyridine derivatives as potential JAK2 inhibitors: a rational strategy for promising anticancer agents